Sign in

Private company

Bakhu Holdings, Corp.

American patent owners and lessors company based in Long Beach1

In its 2026 annual report the company says: “We hold a license from Cell Science to plant cell-extraction and replication technology and related proprietary equipment, processes, and formulations, to produce, manufacture, and sell cannabis-related byproducts - sometimes referred to as cannabinoids—exclusively in North America, Central America, and the Caribbean for medical, food additive, and recreational uses. We do not currently, and have no intention to produce, manufacture or sell cannabis-related byproducts.”4

Last updated Oct 21, 2026.

Overview

$0Revenue, fiscal 20242
-$3.4MNet income, fiscal 20242
  • IndustryPatent Owners & Lessors1
  • HeadquartersLong Beach, California1
  • Incorporated inNV3
  • Business addressOne World Trade Center, Suite 130, Long Beach, Ca 908313
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We hold a license from Cell Science to plant cell-extraction and replication technology and related proprietary equipment, processes, and formulations (the “Licensed Science”), to produce, manufacture, and sell cannabis-related byproducts - sometimes referred to as cannabinoids—exclusively in North America, Central America, and the Caribbean for medical, food additive, and recreational uses. We do not currently, and have no intention to produce, manufacture or sell cannabis-related byproducts. We intend to sublicense the Licensed Science to third party sub-licensees.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Revenue567892$0 in 2024
02018: $0$020182019: $0$020192020: $0$020202021: $0$020212022: $0$020222023: $0$020232024: $0$02024
Operating income567892-$3.1M in 2024−19% since 2018
-$15.0M-$10.0M-$5.0M02018: -$3.8M-$3.8M20182019: -$10.7M-$10.7M2019+180%2020: -$1.1M-$1.1M2020−90%2021: -$6.8M-$6.8M2021+526%2022: -$12.6M-$12.6M2022+85%2023: -$10.0M-$10.0M2023−20%2024: -$3.1M-$3.1M2024−69%
Net income567892-$3.4M in 2024−10% since 2018
-$20.0M-$15.0M-$10.0M-$5.0M02018: -$3.8M-$3.8M20182019: -$10.7M-$10.7M2019+178%2020: -$1.1M-$1.1M2020−90%2021: -$6.9M-$6.9M2021+523%2022: -$15.5M-$15.5M2022+124%2023: -$10.3M-$10.3M2023−33%2024: -$3.4M-$3.4M2024−67%
Fiscal year2018201920202021202220232024
Revenue$05$06$07$08$09$02$02
Selling, general and admin$14.4K5$40.6K6$108.2K6
Operating expenses$12.6M9$10.0M2$3.1M2
Operating income-$3.8M5-$10.7M6-$1.1M7-$6.8M8-$12.6M9-$10.0M2-$3.1M2
Interest$29.0K5$6686$16.8K7$67.6K8$136.9K9$193.9K2$344.0K2
Income tax$05$06$07$08$09$02$02
Net income-$3.8M5-$10.7M6-$1.1M7-$6.9M8-$15.5M9-$10.3M2-$3.4M2

Compare Bakhu Holdings, Corp. with another company

What it owns

What Bakhu Holdings, Corp. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Properties, in its own words

Our principal executive offices are located at One World Trade Center, Suite 130, Long Beach, California 90831. Our corporate internet address is www.bakhuholdings.com. The reference to our website is an inactive textual reference only and is not a hyperlink. The contents of our website are not part of this Annual Report, and you should not consider the contents of our website in making an investment decision respecting our common stock.

OZ Company, an affiliate, provides our office and office-related equipment and communication facilities, including administrative services, for a fixed monthly fee of $34,000. We intend to find an alternative office facility and enter a long-term office lease with an unaffiliated party at prevailing market rates when increased operations warrant.

The rest of Item 2

In lieu of any reduction to the one-time payment note owed to Cell Science, in January 2022, we accepted the assignment of all rights under the lease with VO Leasing for the 5,000 square-foot facility and all rights in all laboratory equipment and related assets used in the efficacy demonstration testing process located at 15614 Oxnard Avenue, Sherman Oaks, California.

In December 2023 we reached a settlement agreement to restructure this indebtedness owed to VO Leasing Corp., our landlord, and holder of necessary cannabis cultivation and manufacturing licenses in CA. As of July 31, 2024 we were in arrear to VO Leasing in the amount of $276,882 consisting of $260,000 principle and $16,882 in accrued interest. We have defaulted under the terms of the settlement agreement and abandoned the laboratory facility and VO leasing has since disposed of all equipment, machinery and supplies which secured the obligations under the settlement agreement.

Item 2 of the 10-K filed Jul 20, 2026.4

Leadership

Who has led Bakhu Holdings, Corp., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Thomas K. Emmitt2019–2021
  2. Evripides Drakos2022
  3. Michael Richard Hawthorne2022
  4. Teddy Scott Jr.2024

President

  1. Thomas K. Emmitt2019–2021
  2. Evripides Drakos2022
  3. Teddy Scott Jr.2024

Chief financial officer

  1. Thomas K. Emmitt2019–2020
  2. La Sienra Garcia Juan Carlos Garcia2022–2024
20202025
Board members and other officers (10)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Chief Financial OfficerJuan Carlos La Sienra Garcia named Mar 4, 202425

Former names

  • Planet Resources, Corp.Sep 18, 2008 to May 26, 20093

Timeline

  1. Jun 30, 20268-K Entered a material agreement; Change of auditor; Change in control26
  2. Oct 28, 20248-K Change of auditor; Executive or director change; Other events27
  3. May 8, 2024New chief executive Teddy Scott Jr. becomes CEO12
  4. Apr 15, 20248-K Executive or director change28
  5. Mar 5, 20248-K Entered a material agreement; Change to shareholders' rights; Change in control29
  6. Oct 25, 20238-K Other events30
  7. Jun 1, 20238-K Executive or director change31
  8. May 9, 20238-K Executive or director change32
  9. Feb 28, 20238-K Executive or director change33
  10. Feb 24, 20238-K Executive or director change34
  11. Feb 21, 20238-K Other events35
  12. Dec 12, 20228-K Change of auditor36
  13. Aug 4, 20228-K Executive or director change; Other events37
  14. Apr 26, 2022New chief executive Michael Richard Hawthorne becomes CEO14
  15. Jan 25, 2022New chief executive Evripides Drakos becomes CEO13
  16. Dec 16, 2019New chief executive Thomas K. Emmitt becomes CEO15

Filings

118 filings to the SEC since October 2021: 5 annual reports, 16 quarterly reports, 19 major events, 51 insider forms, 1 private raises, 26 other. The latest 20:

  1. Sep 29, 202610-Q BAKHU HOLDINGS, CORP. - FORM 10-Q SEC FILING EDGAR
  2. Sep 23, 202610-Q BAKHU HOLDINGS, CORP. - FORM 10-Q SEC FILING EDGAR
  3. Sep 14, 202610-Q BAKHU HOLDINGS, CORP. - FORM 10-Q SEC FILING EDGAR
  4. Jul 20, 202610-K BAKHU HOLDINGS, CORP. - FORM 10-K SEC FILING EDGAR
  5. Jun 30, 20268-K BAKHU HOLDINGS, CORP. - FORM 8-K SEC FILING EDGAR
  6. Oct 28, 20248-K BAKHU HOLDINGS, CORP. - FORM 8-K SEC FILING EDGAR
  7. Jun 20, 202410-Q BAKHU HOLDINGS, CORP. - FORM 10-Q SEC FILING EDGAR
  8. Jun 13, 2024NT 10-Q BAKHU HOLDINGS, CORP. FORM NT 10-Q EDGAR
  9. May 8, 20243 PRIMARY DOCUMENT EDGAR
  10. May 2, 20244 PRIMARY DOCUMENT EDGAR
  11. May 2, 20245 PRIMARY DOCUMENT EDGAR
  12. May 2, 20244 PRIMARY DOCUMENT EDGAR
  13. May 2, 20245 PRIMARY DOCUMENT EDGAR
  14. May 2, 20244 PRIMARY DOCUMENT EDGAR
  15. May 2, 20244 PRIMARY DOCUMENT EDGAR
  16. May 2, 20245 PRIMARY DOCUMENT EDGAR
  17. Apr 15, 20248-K BAKHU HOLDINGS, CORP. - FORM 8-K SEC FILING EDGAR
  18. Mar 25, 202410-Q BAKHU HOLDINGS, CORP. - FORM 10-Q SEC FILING EDGAR
  19. Mar 11, 2024NT 10-Q BAKHU HOLDINGS, CORP. FORM NT 10-Q EDGAR
  20. Mar 5, 20248-K BAKHU HOLDINGS, CORP. - FORM 8-K SEC FILING EDGAR

The 118 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$1.0M 2024–2024
Money received by yearMoney received by year, 2024–2024: $1.0M in all. Private raises (Form D) $1.0M.$0$500K$1M$1.5M2024 · Private raises (Form D): $1.0M2024
Figures by year
YearPrivate raises (Form D)Total
2024$1.0M$1.0M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Feb 26, 2024Raised $1 million in a private offering of debt25 Form D: $20 million offered in all Form D

SEC filer profile

How Bakhu Holdings, Corp. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBakhu Holdings, Corp.1
  • CIK0001440153
  • Employer ID (EIN)26-05106494
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inNevada4
  • Fiscal year endsJuly 311
  • Industry code (SIC)6794 Patent Owners & Lessors1
  • SEC reviewing officeOffice of Real Estate & Construction, Division of Corporation Finance1
  • Business addressOne World Trade Center, Suite 130, Long Beach, CA 908311
  • Phone858-682-25281
  • Shares outstanding301,302,983 as of Sep 25, 202611
  • Public float$1.0M as of 4
  • AuditorValley Stream, New York PCAOB ID 8224
  • On EDGAR sinceSep 18, 20081
  • Filings231 in all: 8-K (43), 10-Q (33), 4 (29), 5 (28), NT 10-Q (14), 3 (12), 424B3 (11), 10-K (9)1
    All 23 form types

    10-Q/A (8), NT 10-K (7), CORRESP (5), UPLOAD (5), D (4), S-1/A (4), 4/A (3), DEF 14C (3), EFFECT (3), S-1 (3), 10-K/A (2), PRE 14C (2), 10-12G (1), 10-12G/A (1), SC 13G (1)

  • Latest filingsAnnual report (10-K) Jul 20, 2026
    Quarterly report (10-Q) Sep 29, 2026
    Latest 8-K (8-K) Jun 30, 2026

Risk factors and legal proceedings

The risks Bakhu Holdings, Corp. names in Item 1A of its 10-K filed Jul 20, 2026: 60 risks under these headings, as written.4

  • Risks Related to Ukrainian Crises and 2026 Iran War
  • Russia’s recent military intervention in Ukraine and Iran and the international community’s responses have created substantial political and economic disruption, uncertainty, and risk.
  • Risks Related to our Business
  • Our entire business relies on the commercial-scale validation of our licensed cell-extraction and replication technology.
  • We cannot accurately predict when planned further work on our licensed technology will be completed satisfactorily.
  • Our licensed proprietary cannabinoid production technology has only been tested on a limited basis by related parties without qualified third-party replication.
  • Our license from Cell Science may be terminated if we fail to meet certain covenants, which could adversely affect our commercialization program.
  • We have defaulted under a Promissory Note Payable to OZ Company
  • We are obligated to pay Cell Science a one-time payment of $3.5 million.
  • We are obligated to pay OZ Company under a Working Capital Promissory Note.
  • Our ability to attract and enter joint ventures, strategic alliances, or sublicenses with producers, distributors, and sellers is uncertain.
  • We cannot ensure that we will be able to transfer the required technical know-how respecting our licensed technology to enable commercial partners to commercially produce cannabinoids.
The other 50 risks
  • Our long-term success will depend on the profitability of our commercialization arrangements, which we cannot control or predict.
  • Others may challenge the validity and enforceability of the licensed patents, trade secrets, and related intellectual property.
  • The markets for cannabinoid products may not grow at the rate projected by industry market data or at all.
  • Consumers may consider our licensed technology will result in a genetically modified organism.
  • Subsequent clinical or laboratory research on the characteristics of cannabinoids or their effects could adversely affect public attitudes and consumer perception towards cannabinoids and, ultimately, the commercialization of our licensed technology.
  • We may encounter difficulties and increased costs in arranging a new suitable laboratory for our equipment and further technology testing.
  • Third parties may refuse to do business with us if they perceive that we are too closely connected to the cannabis industry.
  • Risks Related to Significant Regulation
  • The activities of our potential commercial partners are highly regulated by extensive and complex federal and state regulatory regimes that make maintaining compliance difficult and challenging.
  • We are subject to various state regulations governing the production, transportation, and sale of cannabinoids generally that can severely restrict our ability to execute our business plan.
  • We cannot ensure that state and local regulatory regimes will accommodate our plant cell-extraction and replication cannabinoid production technology.
  • Strict enforcement of federal laws regarding cannabis would likely severely restrict our ability to execute our business plan.
  • Anticipated relaxation of regulatory restraints may not materialize.
  • The Rohrabacher-Farr Amendment may not be renewed.
  • We and our commercial partners may have difficulty accessing the services of banks, which may make it difficult to sell our products and services.
  • We are subject to certain federal regulations relating to currency transactions.
  • We are subject to risk of civil asset forfeiture.
  • Our commercial partners may be subject to compliance with laws and regulations governing cannabis in foreign jurisdictions.
  • Prohibitions or restrictions from investing in, or transacting business with, companies in the cannabis industry may have an adverse effect on our operations.
  • We may rely on foreign advisors and consultants respecting local legal, regulatory, or governmental requirements or business practices.
  • There remains doubt and uncertainty that we will be able to legally enforce contracts.
  • We would suffer severe penalties and other consequences if we or our agents are found to be in violation of the Foreign Corrupt Practices Act or anti-bribery laws.
  • Our business may be adversely affected by the environmental regulations applicable to the businesses of our commercial partners.
  • We will be subject to Federal Trade Commission and state regulation of business opportunities in connection with our commercialization activities.
  • Risks Related to our Company
  • Unless we are able to bring our delinquent period reports current, our registration may be revoked.
  • Our efforts to obtain adequate external financing have been and likely will continue to be affected by our negative working capital, substantial past due indebtedness, and other factors.
  • Our current and future efforts to obtain additional financing may be adversely affected by the amount of our past due indebtedness, including amounts due to related parties.
  • Rising prevailing interest rates, inflation, and their economic consequences have depressed the securities markets generally and the market for our common stock, which adversely affects our efforts to obtain external funding.
  • We cannot ensure that we will be able to successively reorganize our board of directors and management in order to commercialize our licensed technology.
  • Certain of our officers and directors have been and are subject to substantial conflicts of interest in dealings with Cell Science and others.
  • Our Code of Ethics may not apply or may be waived.
  • The auditor’s reports for the years ended July 31, 2024 and 2023, and previous periods contain explanatory paragraphs about our ability to continue as a going concern.
  • We have identified material weaknesses in our internal control over financial reporting that may cause us to fail to meet our reporting obligations or result in material misstatements of our financial statements.
  • We have a limited operating history.
  • We have not generated any revenue since our inception, and we may never achieve profitability.
  • Our ability to successfully implement a commercialization strategy does not ensure our profitability.
  • We are a smaller reporting company, which reduces our reporting obligations.
  • Unsolicited takeover proposals may distract management and adversely affect our business.
  • We rely on key personnel and consultants.
  • We may incur product liability claims related to the application of the intellectual property we commercialize for cannabinoid production.
  • Our business could be adversely impacted by failures or interruptions of information technology systems and potential cyber-attacks.
  • Ongoing domestic and international financial conditions will adversely affect our business and operations, our prospective commercial partners, the cannabinoid industry, and the world generally.
  • We cannot ensure that we will be able to compete successfully.
  • There is an ongoing dispute between a minority stockholder Mentone, Ltd., and its other stockholders respecting the minority stockholder’s removal from Mentone’s board and Mentone’s purportedly unauthorized transactions related to the licensed cell replication technology.
  • Risks Related to our Common Stock
  • Our Common Stock is Quoted on the Expert Market of the OTC Markets Group
  • Our Common Stock is only Eligible for Unsolicited Quotes
  • The market for our common stock is volatile.
  • We may issue common stock in the future, which may dilute a stockholder’s holdings in our company, including the investors in this offering, or have a negative effect on the market price of our stock.
  • Limited trading volumes for our common stock may limit the ability of our stockholders to obtain liquidity.
  • We do not anticipate paying dividends.
  • The regulated nature of our business may impede or discourage a takeover.

Legal proceedings

From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. To the best of our knowledge, we are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, operating results, financial condition, or cash flows. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
    SEC EDGAROther events
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
    SEC EDGAROther events
  36. 36
  37. 37